Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients.

Westbrook BC, Norwood TG, Terry NLJ, McKee SB, Conry RM.

JAAD Case Rep. 2019 Aug 29;5(9):782-786. doi: 10.1016/j.jdcr.2019.06.034. eCollection 2019 Sep. No abstract available.

2.

Correlates of response and outcomes with talimogene laherperpvec.

Zhou AY, Wang DY, McKee S, Ye F, Wen CC, Wallace DE, Ancell KK, Conry RM, Johnson DB.

J Surg Oncol. 2019 Sep;120(3):558-564. doi: 10.1002/jso.25601. Epub 2019 Jul 2.

PMID:
31264725
3.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM.

Pigment Cell Melanoma Res. 2019 Jul;32(4):553-563. doi: 10.1111/pcmr.12775. Epub 2019 Mar 3.

PMID:
30767428
4.

Sorafenib for Advanced and Refractory Desmoid Tumors.

Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK.

N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052.

5.

Clinical characterization of colitis arising from anti-PD-1 based therapy.

Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB.

Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019.

PMID:
30546965
6.

E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.

Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM.

Clin Cancer Res. 2019 Jan 15;25(2):524-532. doi: 10.1158/1078-0432.CCR-18-2258. Epub 2018 Nov 12.

PMID:
30420448
7.

Pathological complete response after neoadjuvant pembrolizumab and radiation.

Mynard JN, Conry RM, De Los Santos J, Gordetsky JB, Contreras CM.

Clin Exp Dermatol. 2019 Jul;44(5):570-573. doi: 10.1111/ced.13820. Epub 2018 Nov 7. No abstract available.

PMID:
30402885
8.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

PMID:
30021908
9.

Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?

Middlebrooks EH, Westbrook BC, Conry RM.

Radiol Case Rep. 2017 Oct 20;13(1):89-91. doi: 10.1016/j.radcr.2017.09.008. eCollection 2018 Feb.

10.

Talimogene laherparepvec: First in class oncolytic virotherapy.

Conry RM, Westbrook B, McKee S, Norwood TG.

Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846. doi: 10.1080/21645515.2017.1412896. Epub 2018 Feb 22. Review.

11.

Malignant Ewing-Like Neoplasm With an EWSR1-KLF15 Fusion: At the Crossroads of a Myoepithelial Carcinoma and a Ewing-Like Sarcoma. A Case Report With Treatment Options.

Stevens TM, Qarmali M, Morlote D, Mikhail FM, Swensen J, Gatalica Z, Siegal GP, Conry RM.

Int J Surg Pathol. 2018 Aug;26(5):440-447. doi: 10.1177/1066896918755009. Epub 2018 Feb 1.

PMID:
29390927
12.

Smoldering myocarditis following immune checkpoint blockade.

Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM.

J Immunother Cancer. 2017 Nov 21;5(1):91. doi: 10.1186/s40425-017-0296-4.

13.

Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.

Everett AS, Pavlidakey PG, Contreras CM, De Los Santos JF, Kim JY, McKee SB, Kaufman HL, Conry RM.

J Cutan Pathol. 2018 Jan;45(1):48-53. doi: 10.1111/cup.13048. Epub 2017 Oct 26.

PMID:
28940544
14.

Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy.

Marcrom S, De Los Santos JF, Conry RM.

Clin Sarcoma Res. 2017 Jul 14;7:14. doi: 10.1186/s13569-017-0079-1. eCollection 2017.

15.

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec.

Blackmon JT, Stratton MS, Kwak Y, Pavlidakey PG, Slominski AT, McKee SB, Viator TM, Kim JY, Huang CC, Conry RM.

JAAD Case Rep. 2017 Jun 16;3(4):280-283. doi: 10.1016/j.jdcr.2017.02.011. eCollection 2017 Jul. No abstract available.

16.

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases.

Blackmon JT, Dhawan R, Viator TM, Terry NL, Conry RM.

JAAD Case Rep. 2017 Apr 14;3(3):185-189. doi: 10.1016/j.jdcr.2017.02.003. eCollection 2017 May. No abstract available.

17.

Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.

Blackmon JT, Dhawan R, Terry NL, Conry RM.

Melanoma Res. 2017 Apr;27(2):159-163. doi: 10.1097/CMR.0000000000000318.

PMID:
28252478
18.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.

19.

Responses to immune checkpoint inhibitors in nonagenarians.

Johnpulle RA, Conry RM, Sosman JA, Puzanov I, Johnson DB.

Oncoimmunology. 2016 Oct 18;5(11):e1234572. doi: 10.1080/2162402X.2016.1234572. eCollection 2016.

20.

Primary Intraosseous Smooth Muscle Tumor of Uncertain Malignant Potential: Original Report and Molecular Characterization.

Kropp L, Siegal GP, Frampton GM, Rodriguez MG, McKee S, Conry RM.

Rare Tumors. 2016 Nov 17;8(4):6507. eCollection 2016 Nov 17.

21.

Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma.

Duncan VE, Nabors LB, Warren PP, Conry RM, Willey CD, Perry A, Riley KO, Hackney JR.

Int J Surg Pathol. 2016 Dec;24(8):753-756. Epub 2016 Jul 14.

PMID:
27422470
22.

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

Kanz BA, Pollack MH, Johnpulle R, Puzanov I, Horn L, Morgans A, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB.

J Immunother Cancer. 2016 Oct 18;4:60. eCollection 2016.

23.

Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.

Kropp LM, De Los Santos JF, McKee SB, Conry RM.

J Immunother. 2016 Nov/Dec;39(9):373-378.

24.

Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.

Conry RM, Rodriguez MG, Pressey JG.

Clin Sarcoma Res. 2016 Apr 28;6:6. doi: 10.1186/s13569-016-0046-2. eCollection 2016.

25.

A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases.

Fiveash JB, Arafat WO, Naoum GE, Guthrie BL, Sawrie SM, Spencer SA, Meredith RF, Markert JM, Conry RM, Nabors BL.

Adv Radiat Oncol. 2016 Apr 1;1(2):83-88. doi: 10.1016/j.adro.2016.03.004. eCollection 2016 Apr-Jun.

26.

Ipilimumab-induced encephalopathy with a reversible splenial lesion.

Conry RM, Sullivan JC, Nabors LB 3rd.

Cancer Immunol Res. 2015 Jun;3(6):598-601. doi: 10.1158/2326-6066.CIR-15-0035. Epub 2015 Apr 28.

27.

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.

Rosenthal EL, Chung TK, Parker WB, Allan PW, Clemons L, Lowman D, Hong J, Hunt FR, Richman J, Conry RM, Mannion K, Carroll WR, Nabell L, Sorscher EJ.

Ann Oncol. 2015 Jul;26(7):1481-7. doi: 10.1093/annonc/mdv196. Epub 2015 Apr 21.

28.

Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.

Seeley AR, De Los Santos JF, Conry RM.

Melanoma Res. 2015 Jun;25(3):246-51. doi: 10.1097/CMR.0000000000000154.

PMID:
25746037
29.

Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review.

Conry RM.

Clin Sarcoma Res. 2014 Jun 28;4:6. doi: 10.1186/2045-3329-4-6. eCollection 2014.

30.

ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).

Go RS, Lee SJ, Shin D, Callister SM, Jobe DA, Conry RM, Tarhini AA, Kirkwood JM.

Clin Cancer Res. 2013 Dec 1;19(23):6597-604. doi: 10.1158/1078-0432.CCR-13-1414. Epub 2013 Oct 11.

31.

Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.

Boyd KP, Vincent B, Andea A, Conry RM, Hughey LC.

J Am Acad Dermatol. 2012 Dec;67(6):1375-9. doi: 10.1016/j.jaad.2012.06.045. Epub 2012 Aug 30. Review.

PMID:
22940405
32.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P.

N Engl J Med. 2011 Jun 2;364(22):2119-27. doi: 10.1056/NEJMoa1012863.

33.

Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.

Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL.

Clin Cancer Res. 2008 Aug 1;14(15):4843-9. doi: 10.1158/1078-0432.CCR-08-0276.

34.

A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.

Forero A, Shah J, Carlisle R, Triozzi PL, LoBuglio AF, Wang WQ, Fujimori M, Conry RM.

Cancer Biother Radiopharm. 2006 Dec;21(6):561-8.

PMID:
17257071
35.

Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.

Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM.

J Immunother. 2005 Jul-Aug;28(4):382-8.

PMID:
16000957
36.

Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.

Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM.

Clin Cancer Res. 2005 Jun 1;11(11):4168-75.

37.

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.

Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM.

Hum Gene Ther. 2005 Jan;16(1):91-100.

PMID:
15703492
39.

Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.

Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF.

Clin Cancer Res. 2002 Sep;8(9):2782-7.

41.

Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine.

White SA, LoBuglio AF, Arani RB, Pike MJ, Moore SE, Barlow DL, Conry RM.

J Gene Med. 2000 Mar-Apr;2(2):135-40.

PMID:
10809147
42.

SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma.

Hampton TA, Conry RM, Khazaeli MB, Shaw DR, Curiel DT, LoBuglio AF, Strong TV.

Cancer Gene Ther. 2000 Mar;7(3):446-55.

43.

Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine.

Conry RM, Allen KO, Lee S, Moore SE, Shaw DR, LoBuglio AF.

Clin Cancer Res. 2000 Jan;6(1):34-41.

44.

Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.

Conry RM, Khazaeli MB, Saleh MN, Allen KO, Barlow DL, Moore SE, Craig D, Arani RB, Schlom J, LoBuglio AF.

Clin Cancer Res. 1999 Sep;5(9):2330-7.

45.

Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen.

Conry RM, White SA, Fultz PN, Khazaeli MB, Strong TV, Allen KO, Barlow DL, Moore SE, Coan PN, Davis I, Curiel DT, LoBuglio AF.

Clin Cancer Res. 1998 Nov;4(11):2903-12.

46.
47.

Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells.

Conry RM, Bantia S, Turner HS, Barlow DL, Allen KO, LoBuglio AF, Montgomery JA, Walsh GM.

Immunopharmacology. 1998 Jul;40(1):1-9.

PMID:
9776473
48.

Incorporation of beta-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression.

Strong TV, Hampton TA, Louro I, Bilbao G, Conry RM, Curiel DT.

Gene Ther. 1997 Jun;4(6):624-7.

49.

Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae.

McDaniel LS, Loechel F, Benedict C, Greenway T, Briles DE, Conry RM, Curiel DT.

Gene Ther. 1997 Apr;4(4):375-7.

50.

Polynucleotide-mediated immunization therapy of cancer.

Conry RM, LoBuglio AF, Curiel DT.

Semin Oncol. 1996 Feb;23(1):135-47. Review.

PMID:
8607023

Supplemental Content

Loading ...
Support Center